Mammoth Biosciences
Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.
We may earn a commission from links on this Mammoth Biosciences profile. That does not change the facts we publish.
About
Mammoth Biosciences is developing in vivo gene editing therapeutics using novel CRISPR-Cas enzymes and protein discovery technologies to deliver permanent cures for serious diseases. Their platform also enables limitless testing possibilities through a revolutionary CRISPR-based molecular diagnostics system. The company serves patients by overcoming challenges in genetic medicine and addressing unmet needs for severe conditions. Teams look it up for Biotechnology, Drug Discovery, Genomics.
Frequently asked
What does Mammoth Biosciences do?
Mammoth Biosciences is a Biotechnology company that offers Platform. Teams look it up for Drug Discovery, Genomics, CRISPR Technology. It is based in Brisbane, United States and was founded in 2017. Public records show about 165 people and $460M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Mammoth Biosciences raised?
Mammoth Biosciences has raised a total of $460M in funding. The most recent round on record is Funding Round.
Where is Mammoth Biosciences headquartered?
Mammoth Biosciences is headquartered in Brisbane, United States.
When was Mammoth Biosciences founded?
Mammoth Biosciences was founded in 2017.
What industry does Mammoth Biosciences operate in?
Mammoth Biosciences operates in Biotechnology, Drug Discovery, Genomics, CRISPR Technology, Gene Editing.
How many employees does Mammoth Biosciences have?
Mammoth Biosciences has approximately 165 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.